Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis

被引：118

作者：

Herman, AG

Moncada, S

机构：

[1] Univ Antwerp, Div Pharmacol, B-2610 Antwerp, Antwerpen, Belgium

[2] UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England

来源：

EUROPEAN HEART JOURNAL | 2005年 / 26卷 / 19期

关键词：

nitric oxide; atherosclerosis; nitric oxide donor;

D O I：

10.1093/eurheartj/ehi333

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Well-known risk factors for atherosclerosis include hypercholesterolaemia, hypertension, diabetes, and smoking. These conditions are associated with endothelial dysfunction, which itself is associated with reduced endothelial generation of nitric oxide (NO). This is an overview of the implications of NO generation in atherosclerosis and of the potential therapeutic benefit of drugs which donate NO, such as organic nitrates, nicorandil, and sydnonimines, or those which increase the availability of endogenous NO, such as statins, angiotensin-converting enzyme inhibitors, L-arginine, and tetrahydrobiopterin.

引用

收藏

页码：1945 / 1955

页数：11

相关论文

共 156 条

[1]

Aji W, 1997, CIRCULATION, V95, P430

[2] Nitric oxide and arterial disease [J].

Barbato, JE ;

Tzeng, E .

JOURNAL OF VASCULAR SURGERY, 2004, 40 (01) :187-193

[3] Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris [J].

Bednarz, B ;

Wolk, R ;

Chamiec, T ;

Herbaczynska-Cedro, K ;

Winek, D ;

Ceremuzynski, L .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2000, 75 (2-3) :205-210

[4] Molsidomine improves flow-dependent vasodilation in brachial arteries of patients with coronary artery disease [J].

Belhassen, L ;

Carville, C ;

Pelle, G ;

Sediame, S ;

Benacerraf, S ;

Dubois-Rand, JL ;

Adnot, S .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (04) :560-563

[5] Investigation into the sources of superoxide in human blood vessels - Angiotensin II increases superoxide production in human internal mammary arteries [J].

Berry, C ;

Hamilton, CA ;

Brosnan, J ;

Magill, FG ;

Berg, GA ;

McMurray, JJV ;

Dominiczak, AF .

CIRCULATION, 2000, 101 (18) :2206-2212

[6] Adhesion molecules and atherosclerosis [J].

Blankenberg, S ;

Barbaux, S ;

Tiret, L .

ATHEROSCLEROSIS, 2003, 170 (02) :191-203

[7] Changes in von Willebrand factor and soluble ICAM, but not soluble VCAM, soluble E selectin or soluble thrombomodulin, reflect the natural history of the progression of atherosclerosis [J].

Blann, AD ;

Lip, GYH ;

McCollum, CN .

ATHEROSCLEROSIS, 2002, 165 (02) :389-391

[8] Oral L-arginine in patients with coronary artery disease on medical management [J].

Blum, A ;

Hathaway, L ;

Mincemoyer, R ;

Schenke, WH ;

Kirby, M ;

Csako, G ;

Waclawiw, MA ;

Panza, JA ;

Cannon, RO .

CIRCULATION, 2000, 101 (18) :2160-2164

[9] Asymmetric dimethylarginine, and endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor [J].

Böger, RH .

JOURNAL OF NUTRITION, 2004, 134 (10) :2842S-2847S

[10] ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE-/-/ICAM-1-/-) fed a fat or a chow diet [J].

Bourdillon, MC ;

Poston, RN ;

Covacho, C ;

Chignier, E ;

Bricca, G ;

McGregor, JL .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (12) :2630-2635

← 1 2 3 4 5 6 7 8 9 10 →